ADC Therapeutics SA (ADCT) vs Entrada Therapeutics (TRDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Entrada Therapeutics (TRDA) has outperformed ADC Therapeutics SA (ADCT) over the past year, losing 4.1% versus a loss of 65.0%. Entrada Therapeutics is the larger company by market cap ($215.3 million vs $203.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADCT | TRDA |
|---|---|---|
| Share price | $1.59 | $5.53 |
| Market cap | $202.99M | $215.32M |
| 1-day change | +11.97% | -1.43% |
| YTD return | -54.96% | -45.43% |
| 1-year return | -64.98% | -4.10% |
| 5-year return | -93.76% | — |
| EPS (TTM) | $-0.60 | $-3.96 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.98 | $16.45 |
| 52-week low | $0.78 | $5.15 |
| Distance from 52-week high | -68.07% | -66.38% |
| Analyst consensus | none | none |
| Avg. price target upside | +109.43% | +243.58% |
| Average volume | 1.43M | 359.01K |
| Shares outstanding | 127.67M | 38.94M |
| Employees | 188 | 152 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TRDA has outperformed ADCT by 60.9 percentage points over the past year.
About ADC Therapeutics SA
ADCT stock →ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.
Health Care · Biotechnology: Pharmaceutical Preparations · 188 employees
About Entrada Therapeutics
TRDA stock →Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 152 employees
ADCT vs TRDA FAQ
Which is bigger, ADC Therapeutics SA or Entrada Therapeutics?
Entrada Therapeutics (TRDA) is larger, with a market capitalization of $215.32M compared with $202.99M for ADC Therapeutics SA (ADCT).
Which stock has performed better over the past year, ADCT or TRDA?
TRDA returned -4.10% over the past 12 months, compared with -64.98% for ADCT (price return, excluding dividends). Past performance does not predict future results.
Are ADC Therapeutics SA and Entrada Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.